Abstract
With the advent of more effective therapeutic modalities, better methods to evaluate and quantify minimal residual disease (MRD) in patients with malignant lymphoma are needed. These methods should be highly sensitive in detecting very low amounts of malignant cells and should be specific for the malignant clone. In addition, these methods should allow the quantification of residual tumor cells. At present, the highest sensitivity is reached with PCR, allowing the detection of one malignant cell in 106 normal cells [1]. The clone-specific hypervariable complementarity determining regions (CDRs) of the immunoglobulin heavy chain locus (IgVH) provide a useful marker for monitoring MRD in B-cell lymphoma during and after treatment [2, 3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Roberts W, Estrov Z, Zipf T (1995) Detection of minimal residual disease in acute lymphoblastic leukemia [letter; comment]. Blood 86: 237–9
Maloum K, Pritsch O, Dighiero G (1997) Minimal residual disease detection in B-cell malignancies by assessing IgH rearrangement. Hematol Cell Ther 39: 19–24
Schultze JL, Donovan JW, Gribben JG (1999) Minimal residual disease detection after myeloablative chemotherapy in chronic lymphytic leukemia. J Mol Med 77: 259–265
Zwicky C, Maddocks A, Andersen N, Gribben J (1996) Eradication of polymerase chain reaction detectable immunoglobulin gene rearrangement in non-Hodgkin’s lymphoma is associated with decreased relapse after autologous bone marrow transplantation. Blood 88: 3314–22
Sambrook J, Fritsch EF, Maniatis T (1989) Molecular Cloning: A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor NY
Kueppers R, Hansmann ML, Rajewsky K (1996) Micromanipulation and PCR analysis of single cells from tissue sections. In: Herzenberg LA, Weir D, Blackwell D (eds) Handbook of Experimental Immunology, 5“ edn., Blackwell Science Ltd., Oxford 206.1–206. 4.
Corradini P, Voena C, Astolfi M, Ladetto M, Tarella C, Boccadoro M, Pileri A (1995) High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 85: 596–602
Boleda M, Briones P, Farces J, Tyfield L, Pi R (1996) Experimental design: a useful tool for PCR optimization. Biotechniques 211: 34–40
Wang Z, Spadoro J (1998) Determination of target copy number of quantitative standards used in PCR-based diagnosticassays. In Ferre F (ed) Gene Quantification. Birkhäuser, Boston 33–43
Jeffreys AJ, Wilson V, Neumann R, Keyte J (1988) Amplification of human minisatellites by the polymerase chain reaction: towards DNA fingerprinting of single cells. Nucleic Acids Res 16: 10953–71
Pfitzner T, Engert A, Wittor H, Schinköthe T, Oberhäuser F, Schulz H, Diehl V, Barth S (2000): A real-time PCR assay for the quantification of residual malignant cells in B-cell chronic lymphatic leukemia. Leukemia (in press)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2001 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Pfitzner, T., Engert, A., Barth, S. (2001). Quantification of Residual Tumor Cells in Monoclonal B-cell Lymphoma. In: Meuer, S., Wittwer, C., Nakagawara, KI. (eds) Rapid Cycle Real-Time PCR. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-59524-0_24
Download citation
DOI: https://doi.org/10.1007/978-3-642-59524-0_24
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-66736-0
Online ISBN: 978-3-642-59524-0
eBook Packages: Springer Book Archive